Construction began in May on WuXi Biologics’ €325 million biologics plant in Dundalk, Ireland which is forecast to employ up to 400 when it is finished in 2021. WuXi’s vaccine joint venture has now selected Dundalk to build its first vaccine plant. (WuXi) manufacturing site outside of China. It turns out it likes its Ireland location so much that its vaccine JV will build a plant next door.
WuXi Vaccines last week won approval to build a 15,520-square-meter, three-story vaccine manufacturing facility next to where it is building its biologics facility in Dundalk, Ireland, according to documents first reported by BioProcess International.
There were no financial details about the facility but WuXi Biologics CEO Chris Chen confirmed the project to publication and said it was for a single, yet unnamed, client.
WuXi Vaccines in May announced it had a letter of intent to build a single-client manufacturing facility that will be able to handle substance and drug product manufacturing and will include quality control labs. WuXi didn’t identify the partner but said the deal is to produce $150 million worth of vaccines a year for 20 years.
That deal followed the formation last year of a joint venture between WuXi Biologics and veterinary vaccine maker Shanghai Hile Bio-Technology to create WuXi Vaccines. In a securities filing at the time, WuXi said the venture was being formed to primarily make cancer vaccines.
WuXi, which has already built WuXi City, what it calls China’s largest bioprocessing plant, was enticed by the Ireland Development Association to build in Dundalk its first biologics plant outside of China. WuXi is investing €325 million ($392 million) in the plant, which is slated to employ 400 workers when it is complete in 2021.
Oct 25, 2019